Sign In

Sijme Zeilemaker

CEO at Immunetune

Sijme Zeilemaker is the Chief Executive Officer of Immunetune, a preclinical-stage biotech company developing next-generation DNA vaccines against cancer and infectious diseases.1 He was appointed to this position in August 2021, bringing experience from several oncology biotech companies ranging from preclinical to Phase II clinical development.1

Prior to joining Immunetune, Zeilemaker served as:

  1. Chief Operating Officer, Director Business Development, and Head of Investor Relations at Immunicum AB, a clinical-stage biotech developing cell therapies against cancer.1
  2. Director Business Development at InteRNA Technologies.1
  3. Business development roles at to-BBB technologies and 2-BBB Medicines.1

At Immunetune, Zeilemaker is responsible for leading the company into its next phase of development, leveraging his skillset in business development and investor relations.1 As of January 2025, he continues to serve as the Chief Business Officer (CBO) of Immunetune and is scheduled to attend #JPM2025 in San Francisco.2

Zeilemaker's experience with both big pharma partners and international life science investors positions him well to understand the data and technologies that potential partners and investors seek in the biotech industry.1

Highlights

Immunetune - Drug pipelines, Patents, Clinical trials - Synapse
Jan 1 · ventureradar.com
ImmuneTune - VentureRadar
Aug 11 · biospace.com
Immunetune Strengthens Team by Appointing Sijme Zeilemaker as ...

Related Questions

What are Sijme Zeilemaker's key achievements at Immunetune?
How did Sijme Zeilemaker contribute to the growth of Immunicum AB?
What is the significance of Immunetune's PyroVant™ adjuvant?
How does Immunetune's approach to DNA vaccines differ from other companies?
What are the main challenges Immunetune is currently facing?
Sijme Zeilemaker
Sijme Zeilemaker, photo 1
Sijme Zeilemaker, photo 2
Add to my network

Location

Leiden, South Holland, Netherlands